Sugi Predict

Sugi Predict / Compounds / SCHEMBL15216874

SCHEMBL15216874

SCHEMBL15216874

Cc1cc(C2CC2)cc(C)n1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TLR9 Q9NR96 9/20 0.40
▸ TLR8 Q9NR97 9/20 0.40
▸ TLR7 Q9NYK1 9/20 0.40
▸ POLB P06746 1/20 0.35
▸ APOBEC3G Q9HC16 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.33
▸ CHRM4 P08173 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ PROKR1 Q8TCW9 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ USP2 O75604 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18677138 0.90 PDGFRB (0.40) TLR9TLR8TLR7KDM4ECHRM4
SCHEMBL19537423 0.88 BACE1 (0.41) TLR9TLR8TLR7KDM4ECHRM4
Hydrochloric Acid SCHEMBL28415151 0.87 SPHK1 (0.37) TLR9TLR8TLR7
SCHEMBL28970605 0.85 HRH4 (0.39) TLR9TLR8TLR7KDM4ECHRM4
SCHEMBL25413620 0.84 PDE10A (0.38) TLR9TLR8TLR7PDE10AALDH1A1
SCHEMBL16877319 0.84 TLR9 (0.33) TLR9TLR8TLR7KDM4EALDH1A1
SCHEMBL28325130 0.84 TLR8 (0.39) TLR9TLR8TLR7KDM4EALDH1A1
SCHEMBL10606490 0.84 NOS3 (0.50) TLR9TLR8TLR7PDE10A
SCHEMBL30267735 0.84 TLR9 (0.36) TLR9TLR8TLR7PDE10ACHRM4
SCHEMBL21381385 0.83 ESR2 (0.46) TLR9TLR8TLR7PDE10AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 — — EP claimed
US-9670208-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-06-06 — — US claimed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 — — EP claimed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 — — US claimed
WO-2015103137-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-07-09 — — WO claimed
US-20230124815-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-04-20 — — US disclosed
US-11370786-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-06-28 — — US disclosed
US-20200407353-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2020-12-31 — — US disclosed
US-10766892-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-09-08 — — US disclosed
EP-3677579-A1 HETEROCYCLIC GLS1 INHIBITORS Board of Regents, The University of Texas System (US) 2020-07-08 — — EP disclosed
EP-3164394-B1 GLS1 INHIBITORS FOR TREATING DISEASES UNIV TEXAS (US) 2020-04-01 — — EP disclosed
US-20190270736-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-09-05 — — US disclosed
US-9670208-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-06-06 — — US disclosed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 — — EP disclosed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 — — US disclosed
US-20160009704-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-01-14 — — US disclosed
US-20160009704-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-01-14 — — US disclosed
WO-2016004404-A2 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2016-01-07 — — WO disclosed
WO-2015103137-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-07-09 — — WO disclosed
US-20130225548-A1 Pyridine Derivative and Medicinal Agent NIPPON SHINYAKU CO., LTD. (JP) 2013-08-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124815-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 TLR9 4544/4885TLR8 4370/4885TLR7 4528/4885
US-20160009704-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 TLR9 4544/4885TLR8 4370/4885TLR7 4528/4885
US-10766892-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 TLR9 4544/4885TLR8 4370/4885TLR7 4528/4885
US-11370786-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLB1 TLR9 3456/4885TLR8 3867/4885TLR7 2377/4885
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS TTBK1, MAP3K1, TNNI3K TLR9 3648/4885TLR8 3549/4885TLR7 3380/4885
US-20130225548-A1 Pyridine Derivative and Medicinal Agent NR0B2, NR0B1, CNKSR1 TLR9 3004/4885TLR8 2408/4885TLR7 1380/4885
US-20200407353-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 TLR9 4544/4885TLR8 4370/4885TLR7 4528/4885
US-20190270736-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 TLR9 4544/4885TLR8 4370/4885TLR7 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.